Clinical characteristics of retreated bacterial negative pulmonary tuberculosis patients

doi:10.3969/j.issn.1000-6621.2021.10.006

Abstract

Abstract:

Objective To analyze the clinical characteristics of retreated bacterial negative pulmonary tuberculosis in order to improve the diagnosis. Methods A retrospective study was conducted in 201 patients with retreated pulmonary tuberculosis diagnosed and hospitalized in Guangzhou Chest Hospital from February 1, 2020 to July 31, 2020. According to the results of the acid-fast bacilli smear or culture of secretions before treatment, these patients were divided into bacterial positive group (n=146) and bacterial negative group (n=55). The treatment history and clinical data were collected, age, gender, treatment history, drug resistance, clinical symptoms, imaging findings and complications in the two groups were compared. Results (1) Treatment history: among the 201 subjects, 148 (73.6%) patients needed retreatment after drug withdrawal, and 53 (26.4%) patients failed in the initial treatment. Of the 148 patients needed retreatment, 110 (75.3%) in bacterial positive group and 38 (69.1%) in bacterial negative group, the difference of distribution was no statistically significant (χ²=0.804, P=0.375). (2) Clinical symptoms: cough were found 100.0% (n=55) in the bacteria negative group, significantly higher than that in the bacteria positive group (n=127, 87.0%) (χ²=7.905, P=0.005). Fourteen (25.5%) patients in bacterial negative group were found with symptoms of tuberculosis poisoning, significantly lower than that in bacterial positive group (n=61, 41.8%)(χ²=4.553, P=0.033). (3) Imaging findings: 23.6% (13/55) in bacterial negative group had ≥3 cavities in lung lesions, significantly lower than that in bacterial positive group (53.4%, 78/146) (χ²=14.308, P<0.001). (4) Complications: the main type of bronchial tuberculosis in the two groups was scar stenosis. It occurred in 85.7% (12/14) patients of the bacterial negative group, significantly higher than in the bacterial positive group (60.0%, 33/55) (χ²=3.996, P=0.046). Serum albumin ≤40 g/L in 29.1% (16/55) patients in bacterial negative group, significantly lower than in bacterial positive group (54.1%, 79/146)(χ²=10.033, P=0.002). Conclusion Compared with retreated bacterial positive pulmonary tuberculosis, retreated bacterial negative pulmonary tuberculosis patients suffer more cough, less tuberculosis poisoning symptoms, less extensive cavity and hypoproteinemia, and more likely to complicated with scar narrow bronchial tuberculosis.

Key words: Tuberculosis, pulmonary, Retreatment, Disease attributes, Comparative study

CHENG Wu, TAN Shou-yong, LI Yan, LI Qiong. Clinical characteristics of retreated bacterial negative pulmonary tuberculosis patients[J]. Chinese Journal of Antituberculosis, 2021, 43(10): 1006-1009. doi: 10.3969/j.issn.1000-6621.2021.10.006

Figures/Tables 2

References 10

[1]	中华人民共和国国家卫生健康委员会办公厅. 国家卫生健康委办公厅关于印发中国结核病预防控制工作技术规范(2020年版)的通知. 国卫办疾控函〔2020〕279号. 2020-04-02.
[2]	张少俊, 肖和平. 复治肺结核与初治结核病患者外周血T细胞亚群等的变化及其意义. 中华结核和呼吸杂志, 2011, 34(12): 884-887. doi: 10.3760/cma.j.issn.1001-0939.2011.12.002. doi: 10.3760/cma.j.issn.1001-0939.2011.12.002
[3]	黄国军, 高源, 唐细良, 等. 胸腺五肽辅助治疗复治菌阳肺结核疗效和安全性的Meta分析. 中国防痨杂志, 2020, 42(6): 570-577. doi: 10.3969/j.issn.1000-6621.2020.06.007. doi: 10.3969/j.issn.1000-6621.2020.06.007
[4]	谭守勇. 不容忽视耐多药结核病患者营养支持治疗的作用. 中国防痨杂志, 2019, 41(2): 121-123. doi: 10.3969/j.issn.1000-6621.2019.02.001. doi: 10.3969/j.issn.1000-6621.2019.02.001
[5]	杨佳, 吕圣秀, 唐光孝, 等. 初治与复治耐多药肺结核患者的CT表现分析. 中国防痨杂志, 2020, 42(1): 38-43. doi: 10.3969/j.issn.1000-6621.2020.01.010. doi: 10.3969/j.issn.1000-6621.2020.01.010
[6]	Zhao LL, Chen Y, Chen ZN, et al. Prevalence and molecular characteristics of drug-resistance Mycobacterium tuberculosis in Hunan, China. Antimicrob Agents Chemother, 2014, 58(6): 3475-3480. doi: 10.1128/AAC.02426-14. doi: 10.1128/AAC.02426-14 URL
[7]	范大鹏, 岳永宁, 张艳, 等. 2014—2018年杭州市肺结核患者的耐药情况及其影响因素分析. 中国防痨杂志, 2021, 43(1): 72-79. doi: 10.3969/j.issn.1000-6621.2021.01.014. doi: 10.3969/j.issn.1000-6621.2021.01.014
[8]	于海娟, 赵梅, 王佳月, 等. 肺结核患者结核杆菌耐药情况及耐多药结核病的危险因素. 中国感染控制杂志, 2020, 19(1): 58-62. doi: 10.12138/j.issn.1671-9638.20205260. doi: 10.12138/j.issn.1671-9638.20205260
[9]	高会霞, 侯军良, 张志, 等. 346例肺结核患者结核分枝杆菌耐药性调查及耐多药结核病影响因素分析. 中国防痨杂志, 2015, 37(11): 1130-1135. doi: 10.3969/j.issn.1000-6621.2015.11.010. doi: 10.3969/j.issn.1000-6621.2015.11.010
[10]	杜建, 高微微, 马艳, 等. 优化方案和规范化方案对复治肺结核合并糖尿病的疗效. 中华结核和呼吸杂志, 2015, 38(12): 886-891. doi: 10.3760/cma.j.issn.1001-0939.2015.12.003. doi: 10.3760/cma.j.issn.1001-0939.2015.12.003

分组	例数	再治疗[例 (构成比,%)]	停药2年以上再治疗[例 (构成比,%)]	停药2年以内再治疗[例 (构成比,%)]	初治失败[例 (构成比,%)]	2年内再治疗+ 初治失败[例 (构成比,%)]	χ²值	P值
菌阴组	55	38(69.1)	27(49.1)	11(20.0)	17(30.9)	28(50.9)	0.301	0.583
菌阳组	146	110(75.3)	78(53.4)	32(21.9)	36(24.7)	68(46.6)
合计	201	148(73.6)	105(52.2)	43(21.4)	53(26.4)	96(47.8)

临床特点	菌阳组(146例)	菌阴组(55例)	χ²值	P值
性别[例(构成比,%)]			0.103	0.748
男性	112(76.7)	41(74.6)
女性	34(23.3)	14(25.4)
咳嗽	127(87.0)	55(100.0)	7.905	0.005
结核中毒症状	61(41.8)	14(25.5)	4.553	0.033
异烟肼或利福平耐药	67(45.9)	9(16.4)	14.812	<0.001
肺部病灶范围≥3个肺野	131(89.7)	45(81.8)	2.294	0.130
肺部病灶内空洞≥3个	78(53.4)	13(23.6)	14.308	<0.001
并发支气管结核	58(39.7)	14(25.5)	3.539	0.060
血清白蛋白≤40g/L	79(54.1)	16(29.1)	10.033	0.002
CD4⁺T淋巴细胞水平低下	36(24.7)	12(21.8)	0.177	0.674
并发糖尿病	42(28.8)	12(21.8)	0.982	0.322

[1]	Li Leilei, Shi Lei, Wang Lin, Li Hongwei, Xu Liran, Pang Yu, Song Yanzheng. Clinical characteristics analysis of HIV-infected cases diagnosed with tuberculosis after surgery due to pulmonary nodules [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 266-273.
[2]	Song Hongge, Liu Weigao, Chen Li. A comparative study on the therapeutic effects of total hip joint type spacer and pressure model spacer in patients with mid to late stage hip tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(5): 562-566.
[3]	Li Ting, Liu Shuang, Wang Danxia, Lu Jia, Cheng Qianqian, Chen Chuang, He Jin’ge, Zhang Linglin, Xia Yong, Li Jing, Zhang Shu, Gao Wenfeng, Xia Lan. Evaluation of health economics of implementation of tuberculosis prevention and control program in Sichuan Province from 2011 to 2020 [J]. Chinese Journal of Antituberculosis, 2024, 46(3): 333-339.
[4]	Gulina Badeerhan, Liu Nianqiang, Yipaer Aihaiti, Wang Le, Wang Senlu, Zulikatiayi Abudula, Wang Mingzhe, Zhang Jing, Wang Xinqi, Bi Hongbo. The effect of GeneXpert MTB/RIF detection technology in tuberculosis prevention and control program in Xinjiang [J]. Chinese Journal of Antituberculosis, 2024, 46(2): 173-177.
[5]	Ge Jing, Wang Jun, He Yuqi, Nie Wenjuan. Six cases of pseudomembranous colitis caused by anti-tuberculosis drugs and literature review [J]. Chinese Journal of Antituberculosis, 2024, 46(11): 1320-1326.
[6]	Liu Shuren, Fu Lin, Wang Lianbo, Zhao Guisong, Li Zhuo, Dong Zhaoliang. Application of blood management in the perioperative period of lumbar tuberculosis under the concept of enhanced recovery after surgery [J]. Chinese Journal of Antituberculosis, 2024, 46(11): 1343-1349.
[7]	Wang Hanfei, Zhao Yanlin, Xu Caihong. Research progress of subclinical tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(8): 808-813.
[8]	Song Ruixue, Wei Rongrong, Dong Jing, Jia Hongyan, Du Boping, Sun Qi, Xing Aiying, Li Zihui, Zhu Chuanzhi, Zhang Zongde, Pan Liping. The performance of interferon gamma-induced protein 10 mRNA detection technology in auxiliary diagnosis of tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(5): 471-476.
[9]	Yan Xiaojing, Wang Qingfeng, Yang Yang, Chu Naihui, Nie Wenjuan. Diagnostic value of a nanopore sequencing assay of bronchoalveolar lavage fluid in smear-negative pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(5): 487-492.
[10]	Han Xiqin, Wang Jing, Tan Qiuqing, Li Xiaohua, Zhang Liqun, Shao Lingling, Duan Hongfei. Clinical analysis of 93 cases of pulmonary disease caused by nontuberculous mycobacteria [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 355-361.
[11]	Liu Yueyuan, Su Wei, Zheng Jiangang, Wang Meng, Zeng Zhong, Huang Qin, Xie Tian, Li Renzhong. Study on the role of the prefectural tuberculosis designated hospital to improve the case finding of pulmonary tuberculosis in economic undeveloped areas of Jiangxi Province [J]. Chinese Journal of Antituberculosis, 2023, 45(3): 279-284.
[12]	Yao Liming, Yao Xiaowei, Dong Zhaoliang, Liu Fengsheng, Wang Lianbo, Jia Chenguang. Diagnostic value of metagenomic next-generation sequencing in hip or knee tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(3): 292-296.
[13]	Tian Lili, Chen Shuangshuang, Fan Ruifang, Zhang Jie, Wang Nenhan, Chen Hao, Dai Xiaowei, Ren Yixuan, Zhao Yanfeng, Li Chuanyou, Ding Beichuan, Li Bo, Yu Lan, Yi Junli, Wang Pei, Yang Xinyu, Song Weiping. Clinical diagnostic value of combining four methods in detecting etiologically negative pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(2): 144-150.
[14]	Yang Hong, Ma Jinbao, Ren Fei, Li Rong, Wu Yanqin, Zhang Yaohui. Analysis of clinical characteristics of 15 household contacts of patients with drug-resistant pulmonary tuberculosis who developed active pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(2): 172-180.
[15]	Zhao Ailan, Yu Qin, Yu Nan, Zhang Aijie, Xia Hui, Xu Wei. The value of GeneXpert MTB/RIF in improving the laboratory confirmed pulmonary tuberculosis and rifampicin resistance screening at district level institution in Beijing [J]. Chinese Journal of Antituberculosis, 2023, 45(11): 1064-1071.